Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis
|
|
- Norman Floyd
- 5 years ago
- Views:
Transcription
1 (2003) 15, & 2003 Nature Publishing Group All rights reserved /03 $ Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis R Raina 1,2, MM Lakin 1, M Thukral 2, A Agarwal 1,2, S Ausmundson 1, DK Montague 1, E Klein 1 and CD Zippe 1,2 * 1 Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA; and 2 Andrology-Oncology Research Laboratory, Cleveland Clinic Foundation, Cleveland, Ohio, USA Baseline and follow-up data from 102 patients using intracorporeal (IC) injection for erectile dysfunction (ED) following RP were retrospectively collected. We compared baseline International Index for Erectile Function (IIEF) questionnaires with the abridged IIEF-5 questionnaires, referred to as the Sexual Health Inventory of Men (SHIM) to determine drug efficacy. The mean presurgery SHIM score was , which decreased to after surgery and increased to post-treatment. Overall, 68% (69/102) of patients achieved and maintained erections sufficient for sexual intercourse and 48% (49/102) of patients continued long-term therapy with a mean use of y. In all, 52% (53/102) patients discontinued IC therapy. However when excluding patients who switched to oral therapy, had loss of partner or return of normal erections; the compliance to IC injections was 70.6% (71/102). There was no difference in the SHIM analysis between the nerve sparing (NS) and the non-ns or between the types of medications used. IC injections can provide excellent long-term efficacy and compliance in up to 70% of the patients. This study suggests that IC injections are an excellent salvage option in NS patients who fail oral therapy and a first option in patients with non-ns procedures. (2003) 15, doi: /sj.ijir Keywords: radical prostatectomy; erectile dysfunction; intracorporeal penile injections; sildenafil citrate Introduction Although sildenafil citrate has been very successful in treating erectile dysfunction (ED), intracorporeal (IC) penile injections with prostaglandin (PGE1) alone 1,2 or in combination with papaverine and phentolamine 3 continue to be an important therapeutic option. While the use of an oral agent (sildenafil citrate) as a first line agent is optimal, this option in postprostatectomy patients depends on the presence of one or two neurovascular bundles. 4 Patients who had non-nerve-sparing (non-ns) procedures and those who have failed oral therapy will require other options such as IC injections. 5 7 *Correspondence: CD Zippe, Prostate Center Staff, Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. zippec@ccf.org Received 10 January 2003; revised 20 March 2003; accepted 15 April 2003 Dennis and McDougal 8 were the first to document the use of IC (PGE 1) therapy in previously potent RP patients with success rates of 85%. A study by Rodriquez Vela et al 9 in 1999 found that IC PGE1 injection provided adequate rigidity in 95% of their patients. Despite its high degree of effectiveness, patients often do not accept penile injections. Studies show that compliance rates are poor, ranging from 11 to 70%. 1,3,5,6,10 12 Dropout rates in many series exceed 40%. 13 Factors that compromise the success of therapy include: pain associated with the injection, difficulty in reproducing a successful injection, and penile fibrosis. 14 Recent work by Montorsi et al, demonstrated that early postoperative IC injection limited the development of hypoxia-induced tissue damage and produced an overall improvement in the recovery of spontaneous erections. This study opened a new era of interest for the role of IC injections after RP. 7 Since oral therapy demonstrated limited effect in the early postoperative period, IC injections can be used as adjuvant therapy for treatment of RP during the recovery of temporary neuropraxia. 15
2 The literature contains no reports on the longterm effects and durability in patients using IC injections for ED following RP. Therefore, we conducted this study to evaluate the long-term efficacy and compliance of IC injection therapy in a postprostatectomy population and to detail the reasons for its discontinuation. We also sought to determine whether the efficacy of IC injections in postprostatectomy patients is affected by preservation of the neurovascular bundles during surgery or by the type of medication used for injections. Materials and methods Patients We obtained and reviewed the surgical records of a single surgeon (April 1997 to October 2001) who performed radical prostatectomies on 450 sexually active patients with localized prostate cancer. With a mean follow-up of 9 months (6 12 months), 68% (306 /450) patients experienced severe ED with no patient able to achieve vaginal penetration. All 306 patients who sought treatment for ED were initially evaluated by an internist in our group who took a comprehensive sexual history, laboratory evaluation, and physical examination. At that time, the patients were offered standard ED treatments including vacuum constriction device (VCD), intracavernous (IC) injection, or medicated urethral system for erection (MUSE) and since 1998 oral therapy with sildenafil citrate was offered. Of the 306 patients, 102 chose IC injection therapy. We retrospectively stratified these 102 patients according to the type of NS radical prostatectomy procedure they had undergone: bilateral NS (n ¼ 40), unilateral NS (n ¼ 19), and non-ns (n ¼ 43). The surgeon recorded the anatomic status of the neurovascular bundle at the time of surgery; no intraoperative function tests were performed. The type of NS procedure was confirmed by reviewing operative records. Drug therapy The IC regimens used in this study were PGE1 alone (10 or 20 mg/ml in normal saline), high-dose triple therapy (20 mg/ml PGE1+1 mg/ml phentolamine+30 mg/ml papaverine), or low-dose triple therapy (5.88 mg/ml PGE mg/ml phentolamine mg/ml papaverine). Patient training was conducted by an experienced nurse practitioner during two to three office visits and consisted of selection of an appropriate vasoactive agent, dose titration, patient education regarding sterile technique and hemostasis, and partner education. In some cases, the spouse or sexual partner performed the injections if the patient was unable or unwilling to do so. Patients were routinely instructed to change injection sites to prevent corporeal fibrosis and to change their drug regimen (dose and type of IC solution) to ensure effectiveness. All patients were followed at 6- to 9-month intervals. Survey and data assessment The patients response to IC injections was assessed using the International Index of Erectile Function (IIEF-15) questionnaire. 16 A second questionnaire was used to determine the sexual satisfaction of the patients spouses/partners. The spouses/partners were specifically asked how often they were satisfied with intercourse and how often the patient was able to achieve and maintain an erection. This questionnaire was scored from 1 to 5: 1 ¼ never/occasionally; 2 ¼ less than half of the time; 3 ¼ sometimes/half of the time; 4 ¼ more than half of the time; and 5 ¼ almost always. Total spousal satisfaction was calculated from these questions and expressed as a percentage. 4 Patients completed the IIEF-15 questionnaire in the office before (preoperative, baseline) and at mean interval of 9 months (6 12 months) after RP surgery during their follow-up visit. Both surveys were mailed to the 102 patients and their respective spouses/partners. At this time, we also performed a retrospective chart review to collect data on treatment effect, frequency of use, duration of erection following penile injections and side effects. All 102 patients answered IIEF-15 questionnaire and their spouses/partners completed the corresponding spousal questionnaires. Data from the IIEF-15 questionnaire were condensed into the IIEF-5 questionnaire, which is an abridged five-item version of the IIEF-15 questionnaire, referred to as the Sexual Health Inventory of Men (SHIM). The SHIM is a validated, multidimensional, self-administered questionnaire that is a sensitive indicator of changes in erectile function. It is scored from 1 to 5: 1 ¼ never/occasionally; 2 ¼ less than half of the time; 3 ¼ sometimes/half of the time; 4 ¼ more than half of the time; and 5 ¼ almost always. The total IIEF-5 score was calculated by totaling the response to all five questions. 16,17 To be included in the study, participants must have completed the office training, completed the IIEF-15 questionnaire, and reported satisfactory home use. Men were excluded if they received preoperative or postoperative hormonal therapy, radiation therapy, or any concurrent form of therapy for ED. 319
3 320 Statistical analysis The patients were retrospectively stratified according to the type of NS procedure they had undergone: bilateral NS, unilateral NS, or non-ns. The type of surgical procedure was determined by a chart review and confirmed by the questionnaire. Skewness and kurtosis were used to evaluate the distribution of the results. The Wilcoxon signedrank test was used to compare baseline IIEF-5 (SHIM) scores before surgery, before treatment, and after IC injections therapy to determine changes in response. The w 2 test was used to compare categories (NS vs non-ns RP surgery, single therapy vs triple therapy (high- and low-dose). The number of patients discontinuing treatment for multiple reasons was calculated as a percentage of the total. The data are presented using mean, standard deviation, and percentages. A two-tailed significance level of Pr0.05 was used for all statistical tests, and all tests were performed with SAS version 8.0 software. Results The mean follow-up period for all the patients was y, and the mean patient age was y. Of the 102 patients, 40 had a bilateral NS procedure, 19 had a unilateral NS procedure, and 43 had a non-ns procedure. All of the patients had experienced ED for 9 months (6 12 months) after surgery before they started IC injection therapy. Of the 102 patients, 62 (61%) used PGE1 alone, 21 (20%) used low-dose triple therapy, and 19 (19%) used high-dose triple therapy. Overall, 68% (69/102) of the patients achieved and maintained erections sufficient for sexual intercourse; and 48% (49/102) of patients continued long-term therapy with a mean use of y. The duration of erection following penile injection ranged from 9 to 12 min. The ability to achieve vaginal penetration (68%) directly correlated with the spousal satisfaction rate (65%). Table 1 shows that for all SHIM (IIEF-5) domains, scores dropped after surgery but increased significantly after IC injection use. Furthermore, the total mean SHIM score after IC injections use was similar to the total presurgery mean score PZ0.05. There were no statistically significant differences in the IIEF-5 responses between the NS (n ¼ 63) and non- NS (n ¼ 39) groups (Table 2). The frequency of use in the compliant (49/102) subgroup (median, 25 and 75% interquartile range) was four (2, 8) times a month. In the compliant group, there was no significant difference in response for the type of IC solution used: PGE1 (n ¼ 29) or triple therapy (n ¼ 20). Table 1 SHIM (IIEF-5) scores (presurgery, pretreatment, and after IC use) from 102 men with ED caused by radical prostatectomy IIEF-5 domain Presurgery Pretreatment After IC use Q5 Maintenance ability * Q15 Erection confidence * Q4 Maintenance frequency Q2 Erection firmness * Q7 Intercourse satisfaction Total mean IIEF-5 score * Data are presented as mean7s.d. unless otherwise noted. *Po0.05 after RP vs after IC injection IIEF-5 domain was considered as significant. (Each IIEF domain was scored from 0 to 5, 0=did not attempt intercourse, 1=never/occasionally, 2=less than half the time, 3=sometimes/half the time, 4=more than half the time, 5=almost always. The total IIEF-5 score was calculated by totaling and taking the mean of the response of all the five domains of IIEF-5. Table 2 SHIM (IIEF-5) questionnaire responses stratified by type of surgery/treatment with injection SHIM (IIEF-5) Bilateral-NS (n=40) Unilateral-NS (n=19) Non-NS (n=43) Q5 Maintenance ability Q15 Erection confidence Q4 Maintenance frequency Q2 Erection firmness Q7 Intercourse satisfaction Total IIEF Data are presented as mean7s.d. unless otherwise noted. (Each IIEF domain was scored from 0 to 5, 0=did not attempt intercourse, 1=never/occasionally, 2=less than half the time, 3=sometimes/half the time, 4=more than half the time, 5=almost always.) The total IIEF- 5 score was calculated by totaling and taking the mean of the response of all the five domains of IIEF-5.
4 In all, 52% (53/102) patients discontinued IC therapy after a mean use of 14.5 months for the following reasons: insufficient erections, 33% (18/ 53); preference for oral therapy, 32% (17/53); fear of injections, 11% (6/53); troublesome procedure, 11% (6/53); loss of partner, 8% (4/53); priapism, 1% (1/ 53); natural return of erections, 1% (1/53). When including patients who preferred oral therapy to IC injections, who had loss of partners, and return of normal erections, the compliance to IC injections was 70.6% (71/102). The total mean SHIM (IIEF-5) score for the 18 patients who stopped using the IC injections because of a lack of efficacy (insufficient erections) was These 18 patients did not differ from the compliant patients in the type of injection agent used. The type of IC injection solution did not influence the discontinuation rate. The SHIM (IIEF-5) scores and treatment discontinuation rates showed a distinct pattern. Patients with an IIEF-5 score r10 while on IC therapy were much more likely to discontinue treatment [90% (28/31)] than patients with post-therapy IIEF-5 scores Z19 [35% (25/71)]. Discussion In this study, we found that 69 (68%) of our 102 postprostatectomy patients were satisfied with IC injection therapy and that 49/102 (48%) chose to continue with the therapy long-term (mean, 3.5 y). However, including preference to oral therapy (n ¼ 17), loss of partner (n ¼ 4), and return of natural erections (n ¼ 1), the compliance to IC injections was 70.6% (71/102). The type of RP surgery (bilateral NS, unilateral NS, and non-ns) and type of regimen (single, high-dose triple therapy, or lowdose triple therapy) did not affect the efficacy of this therapy. The latter finding is not consistent with the results of a prospective study performed by Bechara et al, 18 who showed that the three-drug mixture is more effective than high-dose PGE1 alone in achieving erections suitable for penetration. However, our satisfaction and compliance rates are similar to those of Mulhall et al 3 and Purvis et al. 6 Using an institutional questionnaire, Mulhall et al found a good response in 75% of their patient group using PGE1, which included patients with ED of all etiologies. 3 They reported an attrition rate of 31% over a 38-month period. Purvis found that 87% of their patient sample (which included patients with ED caused by a variety of etiologies) was fully or partially satisfied with IC injections. Their discontinuation rate in their study was 58% over 2 y. 6 Cost, penile discomfort, and patient partner problems were the major reasons for discontinuation in the Mulhall 3 study. Lack of efficacy was the primary reason for discontinuation in one of seven (14.1%) patients. In the Purvis study, lack of spontaneity, penile discomfort, and cost of therapy were the main reasons for dissatisfaction. Inadequate rigidity or lack of efficacy was the primary reason for discontinuation in 18% of the patients. 6 The primary reasons for discontinuation in our study were inadequate erections and a preference for oral treatment with sildenafil citrate. Like both Mulhall 3 and Purvis, 6 we found side effects to be an infrequent reason for discontinuing treatment. When the response of IC injections is stratified according to the NS status, we found IC injections just as effective in non-ns patients vs patients who had NS procedures (P40.05). Thus, IC injection therapy can be used as contemporary second-line management strategy for NS patients who fail oral therapy and a first option in patients with non-ns procedures. 15 The presence or absence of the neurovascular bundles, which influences the relative amount of nitric oxide secretion significantly, influences a man s ability to achieve vaginal intercourse. With a neurologic injury, there is a decreased release of nitric oxide across the neuromuscular junction, limiting the amount of available cyclic guanosine monophosphate (cgmp). 19,20 The advantage of IC injection agents is that the ensuing smooth muscle relaxation is independent of endogenous vasoactive substance such as nitric oxide production, which is impaired by nerve damage. The degree of smooth muscle relaxation may be more complete with pharmacologically induced erections, so that a patient with a mild venous leak still may veno-occlude to the point of functional erection. 2,21 Our study showed that 32% (17/53) of the patients, who discontinued IC therapy (mean use 1.5 y) switched to sildenafil citrate with acceptable sexual satisfaction. The mean IIEF-5 score of these subgroups was Thus, although injections may be more efficacious than sildenafil citrate, the discomfort and anxiety weigh heavily in the patient s preference for oral therapy. 15,22 Our study suggested that patients who are successfully managed with IC injection therapy should be offered the option of using oral therapy. The compliant patients performed IC injections at a frequency of 4.8 times a month with efficacy scores similar to their presurgery scores. The regular follow-up and comprehensive training that was offered to the patients may have improved compliance. We feel that periodic follow-up combined with realistic expectations increase patient compliance and lowers the attrition rate. Further studies are required to determine if other injectable agents (forskalin, vasoactive intestinal peptide, and moxisylate), alone or in combination, can provide better efficacy and long-term compliance Although penile injection therapy is often not routinely advised in the early postoperative period 321
5 322 because of penile discomfort, patient anxiety or lack of interest, there is some evidence that early rehabilitation of the penis may be necessary to prevent corporeal fibrosis during the neuropraxia period following radical prostatectomy. 7 In our experience, the neuropraxia may persist from 6 to 24 months. 26 This concept supports the study of Montorsi et al of 1997 who demonstrated that early postoperative IC injection limited the development of hypoxia-induced tissue damage and produced an overall improvement in the recovery of spontaneous erections. 7 Since sildenafil citrate shows limited effect in the early postoperative period, the temporary use of IC injections during this time may become an important adjuvant treatment for postprostatectomy patients. 26 Further confirmatory studies are necessary to support this concept that early penile rehabilitation improves long-term penile function. The routine use of IC injection as adjuvant therapy immediately following radical prostatectomy may require the development of new vasoactive agents that produce less penile discomfort and pain. Conclusions IC injections can provide excellent efficacy and compliance in up to 70% of patients, when patients who switched to oral therapy, had loss of a partner, or experienced return of normal erections were included. Comprehensive patients and partner s education may contribute to high compliance rates. IC injections appeared to be just as effective in patients who underwent non-ns prostatectomy as those who had NS procedures. Thus, our study suggests that IC injections are an excellent salvage option in NS patients who fail oral therapy and a first option in patients with non-ns procedures. Whether IC injections can be used as adjuvant therapy in the neuropraxia period following radical prostatectomy may depend on the development of new injectable agents that do not produce pain. References 1 Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: Cawello W et al. Pharmacokineticks of prostaglandin E 1 and its main metabolites after intacavernous injection and short term infusion of prostaglandin E1 in patients with erectile dysfunction. J Urol 1997; 158: Mulhall JP et al. The causes of patient dropout from penile self-injection therapy for impotence. J Urol 1999; 162: Zippe CD et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Eng J Med 1996; 334: Purvis K, Egdetveit I, Christiansen E. Intracavernosal therapy for erectile failurefimpact of treatment and reasons for dropout and dissatisfaction. Int J Impot Res 1999; 11: Montorsi F et al. Recovery of spontaneous erectile function after nerve sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158: Dennis RL, McDougal WS. Pharmacological treatment of erectile dysfunction after radical prostatectomy. J Urol 1988; 139: Rodriguez VL et al. Erectile dysfunction after radical prostatectomy. Etiopathology and treatment. Actas Urol Esp 1997; 21: Irwin MB, Kata EJ. High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994; 43: Vardi Y, Sprecher E, Gruenwald I. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters. J Urol 2000; 163: Sexton WJ, Benedict JF, Jarow JP. Comparison of long-term outcomes of penile prosthesis and intracavernosal injection therapy. J Urol 1998; 159: Lakin MM et al. Prostaglandin E1 injection therapy for postprostatectomy impotence: an outcome analysis. J Urol 1996; 155: Evans C. Complications of intracavernosal therapy for impotence. In: Carson C, Kirby R, Goldstein I (eds). Textbook of Erectile Dysfunction. Isis Medical Media: Oxford, 1999, pp Ajay Nehra. Intracavernosal therapy: when oral agents fail. Cur Urol Rpt 2001; 2: Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: Rosen RC et al. Development and evaluation of an abridged 5-Item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: Bechara A et al. Prostaglandin E1versus mixture of prostaglandin E1, papavereine and phentolamine in non-responders to high papaverine plus phentolamine doses. J Urol 1996; 155: Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157: Burnett AL. Nitric oxide regulation of penile erection: biology and therapeutic implications. J Androl 2002; 23: S20 S Ajay Nehra, Irwin Goldstein. Sildenafil citrate after radical retropubic prostatectomy: con. Urology 1999; 54: De la Taille A, Delmas V, Amar E, Boccon-Gibod L. Reasons for dropout from short-and long-term self-injection therapy for impotence. Europ Urol 1999; 35: Mc Mohan CG. A pilot study of role of intracavernous injection of vasoactive intestinal peptide and phentolamine in the management of erectile failure. Int J Impot Res 1996; 8: Mullhall JP et al. Intracavernosal forskalin: role in management of vasculogenic impotence resistant to 3-agent pharmacotherapy. J Urol 1997; 158: Buvat J et al. Double blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorohydratein chronic organic erectile dysfunction. J Urol 1998; 159: Raina R et al. Management of erectile dysfunction following radical prostatectomy. Curr Urol Rpt 2001; 2:
6
7 Copyright of is the property of Nature Publishing Group and its content may not be copied or ed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or articles for individual use.
LONG-TERM INTRACAVERNOUS THERAPY RESPONDERS CAN POTENTIALLY SWITCH TO SILDENAFIL CITRATE AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY LONG-TERM INTRACAVERNOUS THERAPY RESPONDERS CAN POTENTIALLY SWITCH TO SILDENAFIL CITRATE AFTER RADICAL PROSTATECTOMY RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, SANDRA AUSMUNDSON, DROGO
More informationLONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP
ADULT UROLOGY LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, RAKESH SHARMA, KUSH K. GOYAL, DROGO
More informationIntroduction. RRaina 1,2, A Agarwal 1, S Ausmundson 1,MLakin 1,KCNandipati 1, DK Montague 1, D Mansour 2 and CD Zippe 1
(2006) 18, 77 81 & 2006 Nature Publishing Group All rights reserved 0955-9930/06 $30.00 www.nature.com/ijir ORIGINAL ARTICLE Early use of vacuum constriction device following radical prostatectomy facilitates
More informationLONG-TERM POTENCY AFTER IODINE-125 RADIOTHERAPY FOR PROSTATE CANCER AND ROLE OF SILDENAFIL CITRATE
ADULT UROLOGY CME ARTICLE LONG-TERM POTENCY AFTER IODINE-125 RADIOTHERAPY FOR PROSTATE CANCER AND ROLE OF SILDENAFIL CITRATE RUPESH RAINA, ASHOK AGARWAL, KUSH K. GOYAL, CHERYL JACKSON, JAMES ULCHAKER,
More informationEvidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction
Evidence Review for Surrey Prescribing Clinical Network Treatment: Oral and non-oral combination therapy for erectile dysfunction Prepared by: Linda Honey Topic Submitted by: Prescribing Clinical Network
More informationresponse to MUSE was 70% in the office setting, compared to a 57% success rate when used at home.
Original Article EARLY USE OF MUSE AFTER RP RAINA et al. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful
More informationMANAGEMENT UPDATE , LLC MedReviews
MANAGEMENT UPDATE 2013 MedReviews, LLC rostate cancer is the most common cancer in men over the age of 50 years. 1 When patients undergo a radical prostatectomy (RP), there is a risk of postoperative erectile
More informationERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION. Gregory Harochaw Pharmacy Manager Tache Pharmacy (204)
ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION Gregory Harochaw Pharmacy Manager Tache Pharmacy (204) 233-3469 Nerve Function After careful prostatectomy where the erectile
More informationIC351 (tadalafil, Cialis): update on clinical experience
(2002) 14, Suppl 1, S57 S64 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir IC351 (tadalafil, Cialis): update on clinical experience 1 * 1 Urological practice,
More informationSidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology
Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology (www.intbrazjurol.com.br) glinas@terra.com.br Conflict of Interest: In the
More informationMedicines Q&As. Date prepared: November 2016
Q&A 128.3 What is the rationale and evidence for the use of phosphodiesterase-5 inhibitors as supportive therapy to rehabilitate Erectile Function after nerve sparing radical prostatectomy? Summary Prepared
More information/03/ /0 Vol. 170, , July 2003 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/03/1701-0159/0 Vol. 170, 159 163, July 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000072524.82345.6d COMPARISON OF SATISFACTION
More informationReview Article Overview of Contemporary Penile Rehabilitation Therapies
Hindawi Publishing Corporation Advances in Urology Volume 2008, Article ID 481218, 6 pages doi:10.1155/2008/481218 Review Article Overview of Contemporary Penile Rehabilitation Therapies Peter Hinh and
More informationPenile rehabilitation after radical prostatectomy: patients attitude and feasibility in China
Original Article Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China Yi-Jun Shen 1,2, Jian Li 1,2, Ding-Wei Ye 1,2 1 Department of Urology, Fudan University Shanghai
More informationReview Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
Advances in Urology Volume 2009, Article ID 852437, 4 pages doi:10.1155/2009/852437 Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
More informationRecovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil
Sexual Medicine RECOVERY OF ERECTILE FUNCTION AFTER NERVE-SPARING RP WITH NIGHTLY LOW-DOSE SILDENAFIL BANNOWSKY et al. Associate Editor Michael G. Wyllie Editorial Board Ian Eardley, UK Jean Fourcroy,
More informationPenile Rehabilitation After Radical Prostatectomy: Important Therapy or Wishful Thinking?
MANAGEMENT UPDATE Penile Rehabilitation After Radical Prostatectomy: Important Therapy or Wishful Thinking? Joseph E. Dall Era, MD, Jesse N. Mills, MD, Hari K. Koul, MD, Randall B. Meacham, MD Division
More informationErectile Dysfunction Case Study 2. Medical Student Case-Based Learning
Erectile Dysfunction Case Study 2 Medical Student Case-Based Learning The Case of Mr. Power s Limp Mojo Mr. Powers develops erectile dysfunction after his radical prostatectomy for prostate cancer. You
More informationA Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction
A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction Anthony J. Bella MD, FRCSC Division of Urology, Department of Surgery and Department of Neuroscience
More informationSchemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i
Schemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i M. Lazzeri MD-PhD Department of Urology Ist. Clinico Humanitas IRCCS Schema
More informationAssessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation
www.kjurology.org DOI:.4/kju.2.5.3.22 Sexual Dysfunction/Infertility Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation Jang Ho Bae, Phil Hyun Song, Hyun Tae Kim, Ki Hak
More informationErectile Dysfunction Medical Treatment
1 Erectile Dysfunction Medical Treatment Alireza Ghoreifi Assistant of Urology Mashhad University of Medical Sciences March 2012 2 Treatment of ED Unknown cases of ED First-line therapy Second-line therapy
More informationQuestions & Answers about Sexuality and Intimacy after Bladder Cancer. Part III: Causes and Treatments for Sexual Dysfunction
Questions & Answers about Sexuality and Intimacy after Bladder Cancer A Valentine's chat with Dr. Trinity Bivalacqua Monday, February 13, 2017 Part III: Causes and Treatments for Sexual Dysfunction Presented
More informationCity, University of London Institutional Repository
City Research Online City, University of London Institutional Repository Citation: Lalong-Muh, J., Treacy, C. & Steggall, M.J. (2013). Erectile dysfunction following retropubic prostatectomy. British Journal
More informationOpinion: Yes. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation?
Difference of opinion Vol. 43 (3): 385-389, May - June, 2017 doi: 10.1590/S1677-5538.IBJU.2017.03.03 PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion:
More informationPotency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery
Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery F Van der Aa 1, S Joniau 1, D De Ridder 1 & H Van Poppel 1 * 1 Department
More informationPhosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary
Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-4,23 Agent FDA Approved Dosage and Administration Indication Cialis (tadalafil) (ED) ED; As needed:
More informationMALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
MALE SEXUAL DYSFUNCTION Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara DEFINITION The inability to achieve a satisfactory sexual relationship May involve : - inadequacy
More informationDaily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer
Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) February 2018
More informationErectile Dysfunction Prior Authorization with Quantity Limit Criteria Program Summary
Prior Authorization with Quantity Limit Criteria Program Summary Objective The intent of the prior authorization (PA) program for (ED) is to ensure appropriate selection of patients for treatment according
More informationErectile dysfunction: unmet needs
Erectile dysfunction: unmet needs Dimitris Hatzichristou Professor of Urology / Andrology Director, Center for Sexual and Reproductive Health Aristotle University of Thessaloniki, Greece The numbers MMAS
More informationGUIDELINES ON ERECTILE DYSFUNCTION
16 GUIDELINES ON ERECTILE DYSFUNCTION E. Wespes (chairman), E. Amar, D. Hatzichristou, Dr. F. Montorsi, J. Pryor, Y. Vardi Eur Urol 2002;41:1-5 1. Background, definition and classification Male erectile
More informationREVIEW Sexual dysfunction after pelvic surgery
(2006) 18, 1 18 & 2006 Nature Publishing Group All rights reserved 0955-9930/06 $30.00 www.nature.com/ijir REVIEW C Zippe, K Nandipati, A Agarwal and R Raina Glickman Urological Institute, Cleveland Clinic
More informationGUIDELINES ON ERECTILE DYSFUNCTION
GUIDELINES ON ERECTILE DYSFUNCTION (Text updated March 2005) E. Wespes (chairman), E. Amar, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi, J. Pryor, Y. Vardi 88 Erectile Dysfunction Eur Urol 2001;40:97-101
More informationPolicy #: 370 Latest Review Date: December 2013
Name of Policy: Nerve Graft in Association with Radical Prostatectomy Policy #: 370 Latest Review Date: December 2013 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits
More informationIs This Really a Fair Debate? 2013 MFMER slide-2
Sex Rehab after Radical Prostatectomy: Is it Really Justified? Con Position Landon Trost, MD Assistant Professor of Urology Mayo Clinic, Rochester, MN ISSM 16 th World Meeting on Sexual Medicine October
More informationErectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid
Erectile dysfunction By Anas Hindawi Supervised by Dr Khalid AL Sayyid ED is the persistent/recurrent inability to attain and/or maintain a penile erection rigid enough for satisfactory sexual intercourse
More informationCanadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction
Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction Last reviewed July 2014 Objectives 1. Define erectile dysfunction 2. List and classify the risk factors for erectile dysfunction
More informationErectile Dysfunction: A Primer for Primary Care Providers
Erectile Dysfunction: A Primer for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the definition, incidence and prevalence of Erectile Dysfunction in the U.S. 2. Understand
More informationDisclosure Slide. Dr Michael Gillman IMPOTENCE ERECTILE DIFFICULTIES. Do Men Really Care??? 15/10/2014 ASSESSMENT OF ERECTILE DYSFUNCTION
ASSESSMENT OF ERECTILE DYSFUNCTION Dr Michael Gillman St Andrews Hospital North St Specialist Suites Mater Hospital 3 rd Floor Mater Private Clinic Wesley Hospital Suite 5 Level 9 Evan Thomson Bld Cleveland-
More informationAcceptance of and Discontinuation Rate from Erectile Dysfunction Oral Treatment in Patients following Bilateral Nerve-Sparing Radical Prostatectomy
european urology 53 (2008) 564 570 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Acceptance of and Discontinuation Rate from Erectile Dysfunction Oral Treatment
More informationManaging Erectile Dysfunction
Managing Erectile Dysfunction Lewis E. Harpster MD, FACS Urology of Central PA 4/23/16 1 Objectives 1. Review physiologic mechanism of erection 2. Discuss medical management of ED 3. Discuss surgical management
More informationDifferent hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders
DOI: 10.1111/j.1745-7262.2007.00227.x www.asiaandro.com. Clinical Experience. Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders Shih-Tsung
More informationEffect of penile rehabilitation on erectile function after bilateral nerve-sparing robotic-assisted radical prostatectomy
original article Journal of Andrological Sciences 2010;17:17-22 Effect of penile rehabilitation on erectile function after bilateral nerve-sparing robotic-assisted radical prostatectomy G. Novara, V. Ficarra,
More informationThe effect of sildenafil on electrostimulation-induced erection in the rat model
(2002) 14, 251 255 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The effect of sildenafil on electrostimulation-induced erection in the rat model N Ueno 1,
More informationSexual Dysfunction Caused by Cancer Treatments Issues in Men. Dr Christopher Love
Sexual Dysfunction Caused by Cancer Treatments Issues in Men Dr Christopher Love Urological and Prosthetic Surgeon Bayside Urology 66 Balcombe Rd., Mentone Men s Health Melbourne Level M 233 Collins St.,
More informationERECTILE DYSFUNCTION TREATMENTS
ERECTILE DYSFUNCTION TREATMENTS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage
More informationHigh dose sildenafil citrate as a salvage therapy for severe erectile dysfunction
(2002) 14, 533 538 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction 1 * 1 Australian
More informationMale Sexuality and Cancer. Anne Katz, PhD, RN CancerCare Manitoba August 29, 2012
Male Sexuality and Cancer Anne Katz, PhD, RN CancerCare Manitoba August 29, 2012 Objectives! Recognize the sexual side effects of treatment for cancer in men! Discuss treatment modalities for these problems!
More informationOnset and duration of action of sildena l citrate for the treatment of erectile dysfunction
Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Ian Eardley, 1 Peter Ellis, 2 Mitradev Boolell 2 & Maria Wulff 2 1 Department of Urology, St James University
More informationClinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction
Medicine Update (2004): 11(9), 47-51 Clinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction Dr. Roumen Bostandjiev, Ph.D. Founder and Director of Sexology
More informationPreserved Postoperative Penile Size Correlates Well with Maintained Erectile Function after Bilateral Nerve-Sparing Radical Retropubic Prostatectomy
european urology 52 (2007) 702 707 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Preserved Postoperative Penile Size Correlates Well with Maintained Erectile
More informationManaging Symptoms after Prostate Cancer Sexual Side Effects. Changes in a man s sex life are common and can be managed.
Managing Symptoms after Prostate Cancer Sexual Side Effects Changes in a man s sex life are common and can be managed. Prostate cancer and its treatment often bring changes in a man s sex life, especially
More informationErectile Dysfunction and the Prostate Cancer Patient
BAUN & Prostate cancer UK Erectile Dysfunction Study Day Erectile Dysfunction and the Prostate Cancer Patient Lorraine Montgomery Specialist Nurse Practitioner Urology Queen Elizabeth Hospital Gateshead
More information/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY
0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7
More informationPenile Rehabilitation after Radical Prostatectomy
Penile Rehabilitation after Radical Prostatectomy The PRO Position John P. Mulhall MD MSc FECSM FACS Director, Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center
More informationStrategies for preventing erectile dysfunction induced by radical prostatectomy
Contemporary Urology Archive November 2002 Strategies for preventing erectile dysfunction induced by radical prostatectomy By Edward D. Kim, MD Despite refinements in technique, erectile dysfunction remains
More informationEfficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology
Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology Y. Reisman, MD, PhD. 1, A. Hind, MD. 2, A. Varaneckas, MD. 3, I. Motil, MD. 4 1 Men's Health
More informationClinical Commissioning Policy Proposition:
Clinical Commissioning Policy Proposition: Penile prosthesis surgery for end stage erectile dysfunction Version Number: NHS England B14X10/01 Information Reader Box (IRB) to be inserted on inside front
More informationEndocrine Diagnosis and Treatment
Endocrine Diagnosis and Treatment INTRACAVERNOSAL INJECTION THERAPY AND OTHER TREATMENT OPTIONS FOR ERECTILE DYSFUNCTION Natan Bar-Chama, M.D., Stanley Zaslau, M.D., and Michael Gribetz, M.D. ABSTRACT
More informationDATE BIO# NAME: Last First Middle REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN NAME:
DATE BIO# ERECTILE DYSFUNCTION QUESTIONNAIRE NAME: Last First Middle BIRTHDATE: OCCUPATION: REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN
More informationED treatments: PDE5 inhibitors, injections and vacuum devices
ED treatments: PDE5 inhibitors, injections and vacuum devices Martin Steggall Clinical Nurse Specialist (Erectile Dysfunction and Premature Ejaculation) Barts Health NHS Trust; Associate Dean, Director
More informationORIGINAL INVESTIGATION. Sildenafil for Male Erectile Dysfunction
Sildenafil for Male Erectile Dysfunction A Systematic Review and Meta-analysis ORIGINAL INVESTIGATION Howard A. Fink, MD, MPH; Roderick Mac Donald, MS; Indulis R. Rutks, BS; David B. Nelson, PhD; Timothy
More informationLow Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald
Low Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald Neuro-Urology Unit, Rambam Medical Center & the Technion Faculty of Medicine Haifa, Israel 3 crucial questions
More informationPenile rehabilitation following treatment for prostate cancer: an analysis of the current state of the art
REVIEW Penile rehabilitation following treatment for prostate cancer: an analysis of the current state of the art Tariq Al Shaiji, MD ChB; Trustin Domes, MD; Gerald Brock, MD See related article on page
More informationClinical Policy Title: Penile implant after prostate cancer surgery
Clinical Policy Title: Penile implant after prostate cancer surgery Clinical Policy Number: 13.03.06 Effective Date: October 1, 2017 Initial Review Date: September 21, 2017 Most Recent Review Date: October
More informationPenile rehabilitation following prostate cancer treatment: review of current literature
(2015) 17, 916 922 2015 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com Prostate Cancer Open Access INVITED REVIEW Penile rehabilitation following prostate cancer
More informationASSESSMENT OF PREMATURE EJACULATION AND ERECTILE DYSFUNCTION
ASSESSMENT OF PREMATURE EJACULATION AND ERECTILE DYSFUNCTION Dr Michael Gillman St Andrews Hospital Wickham Terrace Spring Hill Mater Private Clinic, South Brisbane Shore St West Medical Centre, Cleveland
More informationIntracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men
(2001) 13, 317 321 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic
More informationManagement of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction
Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Robert C. Eyre, MD, FACS Associate Clinical Professor of Surgery (Urology) Harvard Medical School Post-prostatectomy Incontinence
More informationClinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents
FORMULARY MANAGEMENT Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents HELEN ELOISE CAMPBELL, BS, PharmD ABSTRACT BACKGROUND: Significant advances in the pharmacologic treatment
More informationPrevention and management of post prostatectomy erectile dysfunction
Review Article Prevention and management of post prostatectomy erectile dysfunction Andrea Salonia 1,2, Giulia Castagna 1, Paolo Capogrosso 1, Fabio Castiglione 1, Alberto Briganti 1,2, Francesco Montorsi
More informationTopical application of a Rho-kinase inhibitor in rats causes penile erection
(2004) 16, 294 298 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Topical application of a Rho-kinase inhibitor in rats causes penile erection Y Dai 1,2,3, K
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 199, by the Massachusetts Medical Society VOLUME 33 M AY 14, 199 NUMBER ORAL IN THE TREATMENT OF ERECTILE DYSFUNCTION IRWIN GOLDSTEIN, M.D., TOM F. LUE, M.D.,
More informationPolicy #: 370 Latest Review Date: April 2017
Name of Policy: Nerve Graft with Radical Prostatectomy Policy #: 370 Latest Review Date: April 2017 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits are payable under
More information, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001
Erectile Dysfunction David Stultz, MD September 10, 2001 Case Presentation A 66 year old male presents to your office requesting Viagra. He states that for the past year he has had difficulty forming
More informationTopical alprostadil (Vitaros ) in the treatment of erectile dysfunction after non-nerve-sparing robotassisted radical prostatectomy
UJ ISSN 0391-5603 Urologia 2017 ; 00 ( 00): 000=000 DOI: 10.5301/uj.5000267 ORIGINAL RESEARCH ARTICLE Topical alprostadil (Vitaros ) in the treatment of erectile dysfunction after non-nerve-sparing robotassisted
More informationAn Update on Pharmacological Treatment of Erectile Dysfunction
An Update on Pharmacological Treatment of Erectile Dysfunction a report by Konstantinos Hatzimouratidis and Dimitrios G Hatzichristou Lecturer in Urology, and Associate Professor in Urology/Andrology and
More informationIntroduction. H Porst
International Journal of Impotence Research (1997) 9, 187±192 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 (medicated urethral system for erection) vs intracavernous AlprostadilÐa comparative
More informationInitial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study
International Journal of Impotence Research (2014), 1 5 2014 Macmillan Publishers Limited All rights reserved 0955-9930/14 www.nature.com/ijir ORIGINAL ARTICLE Initial experience with linear focused shockwave
More informationfor ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology
Tadalafil 5 mg once daily for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Why this conference? Not promotional but educational The pharmacist regularly
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 273 286 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Sexual Medicine Editorial by Dimitris Hatzichristou
More informationGUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation
GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Text update March 2009) E. Wespes, E. Amar, I. Eardley, F. Giuliano, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi,
More informationChronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on Sex Hormones Levels
Australian Journal of Basic and Applied Sciences, 2(3): 779-784, 2008 ISSN 1991-8178 Chronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on
More informationSildenafil Citrate (VIAGRA ) Improves Erectile Function in Elderly Patients With Erectile Dysfunction: A Subgroup Analysis
Journal of Gerontology: MEDICAL SCIENCES 2001, Vol. 56A, No. 2, M113 M119 Copyright 2001 by The Gerontological Society of America Sildenafil Citrate (VIAGRA ) Improves Erectile Function in Elderly Patients
More informationHow to select the right patient for the right treatment: What role does sexuality play in Pca treatment?
How to select the right patient for the right treatment: What role does sexuality play in Pca treatment? Andrea Salonia, MD, PhD, FECSM Università Vita-Salute San Raffaele Director, URI-Urological Research
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2012 Review date: September 2014 Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy JPC Recommendation:
More informationTreatment Program for Erectile Dysfunction in Patients With Cardiovascular Diseases
Treatment Program for Erectile Dysfunction in Patients With Cardiovascular Diseases Solomon Israilov, MD, Jack Baniel, MD, Joseph Shmueli, MD, Eva Niv, MD, Dov Engelstein, MD, Ephraim Segenreich, MD, and
More informationPatient Information ERECTILE DYSFUNCTION. Department of Urology
ERECTILE DYSFUNCTION What is erectile dysfunction? Erectile dysfunction (impotence) is the inability to get or keep an erection sufficient for sexual intercourse. One in ten men (10%) suffer from impotence
More informationErectile Function Before and After Non-Nerve-Sparing Retropubic Radical Prostatectomy
Archives of Urology ISSN: 2638-5228 Volume 1, Issue 2, 2018, PP: 5-9 Erectile Function Before and After Non-Nerve-Sparing Retropubic Radical Prostatectomy Jørgen Bjerggaard Jensen, MD 1, Jørgen K. Johansen,
More informationClinic for urology, pediatric urology and andrology. Penile diseases. Dr. Arne Hauptmann
Clinic for urology, pediatric urology and andrology JUSTUS- LIEBIG UNVERISTY GIESSEN Penile diseases Dr. Arne Hauptmann Clinic for urology, pediatric urology and andrology University Giessen und Marburg
More informationaviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB
aviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB 10 November 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationErectile Dysfunction; It s Not Just About Sex
Erectile Dysfunction; It s Not Just About Sex Disclosures Conflict of interest: I am not paid by Boston Scientific but once in a while they buy me a tasty meal. I do routinely use their products without
More informationProstate Biopsy Protocol in Active Surveillance for Prostate Cancer Causes ED. Con Man: Andrew McCullough May
Prostate Biopsy Protocol in Active Surveillance for Prostate Cancer Causes ED Con Man: Andrew McCullough May 12 2017 It may be particularly useful as an initial screening instrument in a general practice
More informationThe Use of IIEF-5 for Reporting Erectile Dysfunction Following Nerve-Sparing Radical Retropubic Prostatectomy
The Open Prostate Cancer Journal, 2009, 2, 1-9 1 The Use of IIEF-5 for Reporting Erectile Dysfunction Following Nerve-Sparing Radical Retropubic Prostatectomy Open Access Maarten Albersen, Steven Joniau
More informationProstate Cancer and Sexual Function
pissn: 2287-428 / eissn: 2287-469 World J Mens Health 2 August 3(2): 99-17 http://dx.doi.org/1.5534/wjmh.2.3.2.99 Review Article Prostate Cancer and Sexual Function Jae Saog Hyun Department of Urology,
More informationThe efficacy and safety of tadalafil: an update
Original Article C.C. CARSON et al. The efficacy and safety of tadalafil: an update C.C. CARSON, J. RAJFER, I. EARDLEY, S. CARRIER, J.S. DENNE, D.J. WALKER, W. SHEN and W.H. CORDELL Department of Surgery,
More informationPenile Implant Should be Offered Early
Penile Implant Should be Offered Early Landon Trost, MD Assistant Professor in Urology Mayo Clinic, Rochester, MN SMSNA AUA May 16 th, 2015 2013 MFMER slide-1 Clear Indications for Penile Implants Men
More informationavanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL.
avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL. 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationManaging Symptoms after Prostate Cancer Sexual Side Effects for Gay and Bisexual Men Changes in a man s sex life are common and can be managed.
Managing Symptoms after Prostate Cancer Sexual Side Effects for Gay and Bisexual Men Changes in a man s sex life are common and can be managed. Even without prostate cancer, getting older can cause changes
More information